MILAN (AIMnews.it) - Tomorrow will mark the debut on AIM Italia for Kolinpharma. An innovative SME, operating in the nutraceutical sector, expected revenues of € 4.1 million in 2017 (+ 60% on 2016) with an ebitda margin of 15% (10% in 2016) and a net financial debt of around € 2, 5 million. Within the IPO, 447.000 new shares were placed at 7 euros each, with a collection of around 3.1 million euros. With a capital of 1,639,571 shares, the anticipated market capitalisation is 10.2 million and a free float of approximately 27.26%. 180,000 Price Adjustment Shares are also provided for the founding shareholders, Rita Paola Petrelli and Emanuele Lusenti, which may be canceled in favour of the market in the event of failure to achieve certain profitability targets for the financial years 2017 and 2018 (ebitda threshold at € 500.000 and 1.4 million respectively). EnVent Capital Markets is Nomad and Global Coordinator, Emintad, Lombarda & Associati and IR Top Consulting are the financial advisors, Directa Sim the online retailer.